JP2007509143A5 - - Google Patents

Download PDF

Info

Publication number
JP2007509143A5
JP2007509143A5 JP2006536635A JP2006536635A JP2007509143A5 JP 2007509143 A5 JP2007509143 A5 JP 2007509143A5 JP 2006536635 A JP2006536635 A JP 2006536635A JP 2006536635 A JP2006536635 A JP 2006536635A JP 2007509143 A5 JP2007509143 A5 JP 2007509143A5
Authority
JP
Japan
Prior art keywords
pyridin
methanone
chlorophenyl
bistrifluoromethylbenzyl
triazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006536635A
Other languages
English (en)
Japanese (ja)
Other versions
JP4959336B2 (ja
JP2007509143A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/030914 external-priority patent/WO2005042515A1/en
Publication of JP2007509143A publication Critical patent/JP2007509143A/ja
Publication of JP2007509143A5 publication Critical patent/JP2007509143A5/ja
Application granted granted Critical
Publication of JP4959336B2 publication Critical patent/JP4959336B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2006536635A 2003-10-24 2004-10-12 {2−[1−(3,5−ビストリフルオロメチルベンジル)−5−ピリジン−4−イル−1h−[1,2,3]トリアゾル−4−イル]−ピリジン−3−イル}−(2−クロロフェニル)−メタノンの新規の結晶形態 Expired - Lifetime JP4959336B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51430003P 2003-10-24 2003-10-24
US60/514,300 2003-10-24
PCT/US2004/030914 WO2005042515A1 (en) 2003-10-24 2004-10-12 Novel crystalline forms of {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone

Publications (3)

Publication Number Publication Date
JP2007509143A JP2007509143A (ja) 2007-04-12
JP2007509143A5 true JP2007509143A5 (https=) 2007-10-18
JP4959336B2 JP4959336B2 (ja) 2012-06-20

Family

ID=34549327

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006536635A Expired - Lifetime JP4959336B2 (ja) 2003-10-24 2004-10-12 {2−[1−(3,5−ビストリフルオロメチルベンジル)−5−ピリジン−4−イル−1h−[1,2,3]トリアゾル−4−イル]−ピリジン−3−イル}−(2−クロロフェニル)−メタノンの新規の結晶形態

Country Status (28)

Country Link
US (1) US7381826B2 (https=)
JP (1) JP4959336B2 (https=)
KR (1) KR100848407B1 (https=)
CN (1) CN1863791B (https=)
AR (1) AR046131A1 (https=)
AT (1) ATE462700T1 (https=)
AU (1) AU2004285855B8 (https=)
BR (1) BRPI0415010B8 (https=)
CA (1) CA2542140C (https=)
CL (2) CL2009001310A1 (https=)
CR (1) CR8353A (https=)
DE (1) DE602004026333D1 (https=)
DK (1) DK1675846T3 (https=)
EA (1) EA008881B1 (https=)
EC (1) ECSP066517A (https=)
ES (1) ES2340772T3 (https=)
HR (1) HRP20100207T1 (https=)
IL (1) IL174926A0 (https=)
MA (1) MA28329A1 (https=)
MY (1) MY157375A (https=)
NO (1) NO335090B1 (https=)
NZ (2) NZ580480A (https=)
PE (1) PE20050481A1 (https=)
PT (1) PT1675846E (https=)
TW (1) TW200524906A (https=)
UA (1) UA82901C2 (https=)
WO (1) WO2005042515A1 (https=)
ZA (1) ZA200603234B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101568523A (zh) * 2006-12-20 2009-10-28 伊莱利利公司 用于制备{2-[1-(3,5-二-三氟甲基-苄基)-5-吡啶-4-基-1h-[1,2,3]三唑-4-基]-吡啶-3-基}·(2-氯苯基)甲酮的新中间体和方法
WO2009075778A2 (en) * 2007-12-06 2009-06-18 The Regents Of The University Of California Nonpeptidic inhibitors of cruzain
US8080568B1 (en) * 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
CA2978736C (en) 2015-03-04 2023-11-07 Vanda Pharmaceuticals Inc. Dosing regimen of tradipitant
WO2017031215A1 (en) * 2015-08-17 2017-02-23 Eli Lilly And Company Process development of a pyridine-containing nk-1 receptor antagonist
CA3073998A1 (en) 2017-09-13 2019-03-21 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
KR20250140655A (ko) * 2017-11-17 2025-09-25 반다 파마슈티칼즈, 인코퍼레이티드. 트라디피탄트를 이용한 위장 질환의 치료 방법
CN112218636B (zh) * 2018-06-08 2025-05-06 万达制药公司 使用川地匹坦进行治疗的方法
KR102863233B1 (ko) 2018-09-28 2025-09-22 반다 파마슈티칼즈, 인코퍼레이티드. 멀미에서의 트라디피탄트의 용도
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
WO2020117811A1 (en) 2018-12-03 2020-06-11 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
JP2023515167A (ja) 2020-02-25 2023-04-12 バンダ・ファーマシューティカルズ・インコーポレイテッド トラジピタントによるアトピー性皮膚炎の改善された治療
WO2021195205A1 (en) 2020-03-26 2021-09-30 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
WO2023019084A1 (en) 2021-08-12 2023-02-16 Vanda Pharmaceuticals Inc. Treatment of gastric accommodation with tradipitant
US20240350469A1 (en) 2021-08-31 2024-10-24 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
CN120641099A (zh) 2022-12-21 2025-09-12 万达制药公司 使用曲地匹坦的治疗方法
EP4599831A1 (en) 2024-02-09 2025-08-13 Vanda Pharmaceuticals Inc. Treatment of gastroparesis with tradipitant

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020099067A1 (en) * 1993-07-08 2002-07-25 Ulrich Posanski Pharmaceutical compositions for sparingly soluble therapeutic agents
GB9505492D0 (en) * 1995-03-18 1995-05-03 Merck Sharp & Dohme Therapeutic agents
GB9525296D0 (en) * 1995-12-11 1996-02-07 Merck Sharp & Dohme Therapeutic agents
DE69736390T2 (de) * 1996-10-07 2007-07-26 Merck Sharp & Dohme Ltd., Hoddesdon Zns-penetrierende nk-1 rezeptorantagonisten als antidepressivum und / oder anxiolytikum
MXPA02001565A (es) * 1999-08-13 2005-07-14 Vertex Pharma Inhibidores de cinasas c-jun n-terminal (jnk) y de otras cinasas proteicas.
EP1228068A1 (en) * 1999-10-29 2002-08-07 Merck & Co., Inc. Polymorphic form of a tachykinin receptor antagonist
US20020044971A1 (en) * 2000-07-07 2002-04-18 Amidon Gordon L. Dissolution rate of poorly soluble drugs
KR100755577B1 (ko) * 2002-04-26 2007-09-12 일라이 릴리 앤드 캄파니 타키키닌 수용체 길항제로서의 트리아졸 유도체

Similar Documents

Publication Publication Date Title
JP2007509143A5 (https=)
JP3641584B2 (ja) 多形クロピドグレル硫酸水素塩フォーム
JP4624667B2 (ja) 1−4−(5−シアノインドール−3−イル)ブチル−4−(2−カルバモイルベンゾフラン−5−イル)ピペラジン塩酸塩の多形相
JP4336106B2 (ja) 非晶質アトルバスタチンカルシウムの調製
JP2009102357A (ja) Hivプロテアーゼ抑制剤重硫酸塩
JP2004501191A (ja) カルベジロール
JP2007504160A5 (https=)
CA3097312A1 (en) Crystalline forms of a tlr7/tlr8 inhibitor
JP2006514626A5 (https=)
JP2009506014A5 (https=)
RU2000128658A (ru) Тиенилазолилалкоксиэтанамны, их производные и их применение в качестве лекарственных средств
JP2023548160A (ja) 1-(3-シアノ-1-イソプロピル-インドール-5-イル)ピラゾール-4-カルボン酸の結晶性粒子の製造方法およびそれを含む薬学的組成物
JP2005521651A5 (https=)
JP2004525184A5 (https=)
CA2542140A1 (en) Crystalline forms of {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
JP2020073513A (ja) α,ω‐二置換ジヒドロキシシクロペンチル化合物の固体形態、並びにその製造及び使用方法
TWI445697B (zh) 塔適那偉(atazanavir)硫酸氫鹽之製法及其新穎的形式
CA2518999A1 (en) Crystalline and amorphous solids of pantoprazole and processes for their preparation
TWI819279B (zh) 2-[(4s)-8-氟-2-[4-(3-甲氧基苯基)哌嗪-1-基]-3-[2-甲氧基-5-(三氟甲基)苯基]-4h-喹唑啉-4-基]乙酸之鉀鹽
HUP0300596A2 (hu) Amorf toraszemid módosulat, eljárás az előállítására, alkalmazása és ezt tartalmazó gyógyszerkészítmények
JP2018521055A (ja) サクビトリルカルシウム塩
HUP0302135A2 (hu) A toraszemid új V. polimorf módosulata, eljárás előállítására, alkalmazása nyersanyagként, valamint ilyen módosulatot tartalmazó gyógyászati készítmények
CN115427111A (zh) 2-[(4s)-8-氟-2-[4-(3-甲氧基苯基)哌嗪-1-基]-3-[2-甲氧基-5-(三氟甲基)苯基]-4h-喹唑啉-4-基]乙酸钠单水合物、其制备和用途
JP2007528349A (ja) 高い安定性を有する無定形アムロジピンカムシレート、その製造方法及びこれを含む経口投与用組成物
CN115581118A (zh) 制造结晶形式的2-[(4s)-8-氟-2-[4-(3-甲氧基苯基)哌嗪-1-基]-3-[2-甲氧基-5-(三氟甲基)苯基]-4h-喹唑啉-4-基]乙酸钠三水合物的方法